Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use. Objective: To provide consensus statements from the Biosimilar Working Group about the use of biosimilars in patients with psoriasis. Methods: A semi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Elsevier 2020-12-01
Σειρά:	JAAD International
Θέματα:	biosimilars interchangeability International Psoriasis Council psoriasis switching tumor necrosis factor inhibitors
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2666328720300523

Παρόμοια τεκμήρια

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
ανά: Zhou X, κ.ά.
Έκδοση: (2021-07-01)

Biosimilars
ανά: Emel Bülbül Başkan
Έκδοση: (2022-04-01)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
ανά: Alexandra Azevedo, κ.ά.
Έκδοση: (2018-09-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
ανά: Changkun Li, κ.ά.
Έκδοση: (2023-12-01)

Portuguese Position Paper on the Use of Biosimilars in Psoriasis
ανά: Tiago Torres, κ.ά.
Έκδοση: (2016-09-01)

Psoriasis vulgaris with fibrokeratoma from pityriasis amiantacea
ανά: Chihiro Shiiya, MD, κ.ά.
Έκδοση: (2017-05-01)

Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in DenmarkCapsule Summary
ανά: Cæcilie Bachdal Johansen, MD, κ.ά.
Έκδοση: (2022-06-01)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
ανά: Megna M, κ.ά.
Έκδοση: (2022-07-01)

Psoriasis coxsackium
ανά: Daniel W. Cole, MD, κ.ά.
Έκδοση: (2022-07-01)

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
ανά: Rachel C. Ruda, κ.ά.
Έκδοση: (2023-12-01)

A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
ανά: Rebecca Reese, κ.ά.
Έκδοση: (2024-12-01)

Mild-to-moderate severity of psoriasis may be assessed remotely based on photographs and self-reported extent of skin involvementCapsule Summary
ανά: Zarqa Ali, MD, PhD, κ.ά.
Έκδοση: (2023-06-01)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary
ανά: Tamara Gracia Cazaña, MD, PhD, κ.ά.
Έκδοση: (2024-09-01)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
ανά: Kanako Tsunoda, MD, PhD, κ.ά.
Έκδοση: (2024-09-01)

Ustekinumab Biosimilars
ανά: Elena Carmona-Rocha, κ.ά.
Έκδοση: (2024-11-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
ανά: A. A. Soldatov, κ.ά.
Έκδοση: (2019-03-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
ανά: Alan Menter
Έκδοση: (2023-10-01)

Late-onset development of psoriasis in Japan: a population-based cohort studyCapsule Summary
ανά: Haruka Goto, MD, κ.ά.
Έκδοση: (2021-03-01)

On the Regulatory Approval Pathway of Biosimilar Products
ανά: Jun Wang, κ.ά.
Έκδοση: (2012-03-01)

Sociodemographic factors have very little influence on adherence to topical drugs in patients with psoriasis
ανά: Mathias Tiedemann Svendsen, MD, PhD, κ.ά.
Έκδοση: (2024-12-01)

Prognostic implications of high-sensitivity cardiac troponin in patients with suspected myocardial infarction with or without psoriasis
ανά: Sanaz A. Guldmann, MD, DPhil, κ.ά.
Έκδοση: (2023-06-01)

Among psoriasis patients in Flanders, Belgium, a third has sexual dysfunction and almost half depression symptoms
ανά: Roel Van Overmeire, PhD, κ.ά.
Έκδοση: (2025-02-01)

Facial psoriasis in a mask-like distribution
ανά: Cameron M.B. Zachary, MS, κ.ά.
Έκδοση: (2021-01-01)

Injection site reactions due to the use of biologics in patients with psoriasis: A retrospective study
ανά: Yun Kyung Jang, MD, κ.ά.
Έκδοση: (2023-03-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
ανά: Т. V. Korotaeva, κ.ά.
Έκδοση: (2018-12-01)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
ανά: Mohammed Alqahtani, κ.ά.
Έκδοση: (2024-11-01)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
ανά: Cohen SB, κ.ά.
Έκδοση: (2023-10-01)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
ανά: Yuliya Lytvyn, PhD, κ.ά.
Έκδοση: (2022-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
ανά: João Pedro Fernandes, κ.ά.
Έκδοση: (2015-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
ανά: João Pedro Fernandes, κ.ά.
Έκδοση: (2015-01-01)

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet
ανά: Jeffrey A. Bubley, MD, κ.ά.
Έκδοση: (2021-11-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
ανά: Steven R. Feldman, κ.ά.
Έκδοση: (2024-12-01)

Biosimilars, the journey has begun
ανά: Alba Martos-Rosa, κ.ά.
Έκδοση: (2015-01-01)

A pustular psoriasis flare treated with calcium supplementation
ανά: Laure Masson, MD, κ.ά.
Έκδοση: (2021-06-01)

Nanotomography of lesional skin using electron microscopy reveals cytosolic release of nuclear DNA in psoriasis
ανά: Eric Lindberg, PhD, κ.ά.
Έκδοση: (2021-03-01)

The Problem of Anti-Cytokine Therapy in Psoriasis Patients
ανά: Ramina K. Keshileva, PhD
Έκδοση: (2012-09-01)

Cardiovascular Complications During Delivery Hospitalization in Patients With Psoriasis
ανά: Ankit Agrawal, MD, κ.ά.
Έκδοση: (2025-02-01)

Onset of rupioid psoriasis after vasodilatory regimen initiation in a patient with pulmonary arterial hypertension
ανά: Uros Rakita, MSc, κ.ά.
Έκδοση: (2021-06-01)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
ανά: Ronald Vender, MD, κ.ά.
Έκδοση: (2022-09-01)

Societal impact for patients with psoriasis: A nationwide Swedish register studyCapsule Summary
ανά: Henrike Häbel, PhD, κ.ά.
Έκδοση: (2021-06-01)